1. Accueil >
  2. Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline >
Nasdaq

Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline

26-10-2017


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Galapagos NV via GlobeNewswire

HUG#2145124